98 related articles for article (PubMed ID: 20019603)
1. Pulmonary hypertension in thoracic surgical patients.
Ross AF; Ueda K
Curr Opin Anaesthesiol; 2010 Feb; 23(1):25-33. PubMed ID: 20019603
[TBL] [Abstract][Full Text] [Related]
2. Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.
Hall SM; Davie N; Klein N; Haworth SG
Eur Respir J; 2011 Oct; 38(4):851-60. PubMed ID: 21406517
[TBL] [Abstract][Full Text] [Related]
3. Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review.
Demerouti EA; Manginas AN; Athanassopoulos GD; Karatasakis GT; Leontiadis ED; Pavlides GS
Respir Care; 2013 Feb; 58(2):e1-5. PubMed ID: 22710078
[TBL] [Abstract][Full Text] [Related]
4. Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?
Brancaccio G; Toscano A; Bevilacqua M; Di Chiara L; Parisi F
Pediatr Transplant; 2007 Feb; 11(1):110-2. PubMed ID: 17239133
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy and new types of agents for pulmonary arterial hypertension.
O'Callaghan DS; Gaine SP
Clin Chest Med; 2007 Mar; 28(1):169-85, ix. PubMed ID: 17338934
[TBL] [Abstract][Full Text] [Related]
7. Treatments for pulmonary arterial hypertension.
Liu C; Liu K; Ji Z; Liu G
Respir Med; 2006 May; 100(5):765-74. PubMed ID: 16549344
[TBL] [Abstract][Full Text] [Related]
8. Treatment of pulmonary arterial hypertension.
Humbert M; Sitbon O; Simonneau G
N Engl J Med; 2004 Sep; 351(14):1425-36. PubMed ID: 15459304
[No Abstract] [Full Text] [Related]
9. Assessment and treatment of pulmonary arterial hypertension: an Australian perspective in 2006.
Gabbay E; Reed A; Williams TJ
Intern Med J; 2007 Jan; 37(1):38-48. PubMed ID: 17199843
[TBL] [Abstract][Full Text] [Related]
10. Scheduled perioperative switch from oral sildenafil to intravenous epoprostenol in a patient with Eisenmenger syndrome undergoing a sigmoidectomy.
Moriyama K; Uzawa K; Iijima T; Kotani M; Moriyama K; Ohashi Y; Satoh T; Yorozu T
J Clin Anesth; 2012 Sep; 24(6):487-9. PubMed ID: 22762976
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
[TBL] [Abstract][Full Text] [Related]
12. New and future therapies in pulmonary arterial hypertension.
Bull TM
Semin Respir Crit Care Med; 2005 Aug; 26(4):429-36. PubMed ID: 16121320
[TBL] [Abstract][Full Text] [Related]
13. Management of pulmonary arterial hypertension with a focus on combination therapies.
Benza RL; Park MH; Keogh A; Girgis RE
J Heart Lung Transplant; 2007 May; 26(5):437-46. PubMed ID: 17449411
[TBL] [Abstract][Full Text] [Related]
14. Changing the prognosis of pulmonary arterial hypertension: impact of medical therapy.
Chakinala MM
Semin Respir Crit Care Med; 2005 Aug; 26(4):409-16. PubMed ID: 16121318
[TBL] [Abstract][Full Text] [Related]
15. Favorable outcome of pregnancy with an elective use of epoprostenol and sildenafil in women with severe pulmonary hypertension.
Goland S; Tsai F; Habib M; Janmohamed M; Goodwin TM; Elkayam U
Cardiology; 2010; 115(3):205-8. PubMed ID: 20173324
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
17. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
[TBL] [Abstract][Full Text] [Related]
18. Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.
Tofovic SP; Jones TJ; Bilan VP; Jackson EK; Petrusevska G
J Cardiovasc Pharmacol; 2010 Nov; 56(5):475-83. PubMed ID: 20881615
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
20. Therapy with sildenafil or bosentan decreases pulmonary vascular resistance in patients ineligible for heart transplantation because of severe pulmonary hypertension.
Perez-Villa F; Farrero M; Sionis A; Castel A; Roig E
J Heart Lung Transplant; 2010 Jul; 29(7):817-8. PubMed ID: 20363156
[No Abstract] [Full Text] [Related]
[Next] [New Search]
